Jane S. Ricciuti, RPh, MS

Disclosures

July 13, 2004

In This Article

Introduction

The US Food and Drug Administration (FDA) approved labeling changes for the antidepressants Effexor and Effexor XR (venlafaxine), Paxil (paroxetine), Serzone (nefazodone), and Wellbutrin (bupropion hydrochloride).

This month's column reviews FDA new product approvals and labeling changes for:

Anticoagulants

  • Arixtra (fondaparinux sodium) Injection

Antidepressants

  • Effexor and Effexor XR (venlafaxine) Tablets

  • Paxil (paroxetine) Tablets and Oral Suspension

  • Serzone (nefazodone) Tablets

  • Wellbutrin (bupropion hydrochloride) Extended-Release Tablets

Anti-infective Agents

  • Tindamax (tinidazole) Tablets

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....